Skip to main content

Table 3 Health states utility value scores at baseline and follow-up

From: Psychological therapy for mood instability within bipolar spectrum disorder: a randomised, controlled feasibility trial of a dialectical behaviour therapy-informed approach (the ThrIVe-B programme)

Outcomea Baseline 3-month follow-up 6-month follow-up 9-month follow-up 15-month follow-up
ThrIVe-B TAU ThrIVe-B TAU ThrIVe-B TAU ThrIVe-B TAU ThrIVe-B–TAUb (95% CI) ThrIVe-B TAU
EQ-5D-3L 0.52 (0.30)
[− 0.18, 1]
n = 20
  0.65 (0.25)
[0.08, 1]
n = 13
0.59 (0.36)
[− 0.18, 0.85]
n = 14
0.51 (0.31)
[− 0.02, 1]
n = 14
0.65 (0.33)
[− 0.18, 1]
n = 16
0.63 (0.29)
[0.08, 1]
n = 14
0.63 (0.35)
[− 0.08, 1]
n = 17
0.15
(− 0.12, 0.41)
n = 28
0.64 (0.31)
[0.08, 1]
n = 10
0.57 (0.35)
[− 0.02, 1]
n = 16
SF-36 0.58 (0.15)
[0.26, 0.85]
n = 20
0.64 (0.11)
[0.46, 0.86]
n = 20
0.63 (0.12)
[0.39, 0.81]
n = 13
0.63 (0.12)
[0.40, 0.81]
n = 17
0.63 (0.10)
[0.50, 0.86]
n = 14
0.64 (0.13)
[0.40, 0.86]
n = 17
0.64 (0.14)
[0.37, 0.88]
n = 13
0.60 (0.13)
[0.32, 0.88]
n = 16
0.11
(0.01, 0.20)
n = 29
0.65 (0.12)
[0.43, 0.85]
n = 10
0.62 (0.11)
[0.45 0.88]
n = 15
  1. aOutcomes are reported as mean (SD) [range] unless otherwise stated
  2. bAdjusted for site, base use of bipolar disorder medication and baseline score